Abiraterone acetate, which targets enzymatic complexes playing a central role in steroidogenesis, demonstrated to increase survival significantly in both chemo-naive and docetaxel pretreated, becoming one of the drugs of choice for metastatic castration-resistant prostate cancer. More recently, this agent in combination to androgen deprivation therapy demonstrated to be efficacious also in metastatic castration-sensitive prostate cancer. The present review is aimed to outline the clinical development of abiraterone acetate, the pivotal trials which led to its approval for the clinical practice, new evidence about its efficacy in metastatic castration-sensitive prostate cancer, its place in the therapeutic landscape of prostate cancer and future directions of development.
Future oncology (London, England). 2018 Jan 19 [Epub ahead of print]
Orazio Caffo, Antonello Veccia, Stefania Kinspergher, Francesca Maines
Medical Oncology Department, Santa Chiara Hospital, Largo Medaglie d'Oro, Trento 38122, Italy.